Drug Discovery World

JANUARY 11, 2024

Researchers have used messenger RNA (mRNA) to create an effective therapy for a rare liver disease in preclinical studies, demonstrating the technology’s potential therapeutic use in people. Patients affected by the disease are found to also experience an imbalance of glutathione regulation, which is important for liver detoxification.

Disease 147

Disease Research RNA Therapies 147

Drug Discovery World

MAY 17, 2024

From a weight loss drug that prevents heart attacks and a gene therapy that restores hearing, to a vaccine that can treat viruses that don’t exist yet, our chosen news stories this week all represent potential breakthroughs in their respective fields.

Therapies 130

Therapies Vaccine RNA Clinical Trials 130

Drug Discovery World

MARCH 17, 2023

The Scottish Medicines Consortium (SMC) has become the first UK health authority to permit routine NHS use of Gilead Sciences’ Hepcludex (bulevirtide) for the treatment of chronic hepatitis delta virus (HDV) infection. HDV infection is rare, but the effects of chronic HDV infection are potentially extremely serious.

Virus 130

Virus Regulations Licensing Licensing 130

Drug Discovery World

NOVEMBER 15, 2022

An experimental therapeutic cancer vaccine induced immune system responses that led to significant tumour regression in mice, according to investigators from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. .

Vaccine 130

Vaccine Immune Response Virus Disease 130

Drug Discovery World

MAY 21, 2024

From a weight loss drug that prevents heart attacks and a gene therapy that restores hearing, to a vaccine that can treat viruses that don’t exist yet, our chosen news stories this week all represent potential breakthroughs in their respective fields.

Virus 147

Virus Vaccine Therapies Drugs 147

Drug Discovery World

OCTOBER 27, 2023

My news highlights this week feature a variety of treatment approaches, from cell therapy and antibody-drug conjugate to autotaxin inhibitor and arenaviral vaccine, all entering early in-human clinical trials to treat a range of diseases.

Vaccine 130

Vaccine Drugs Therapies Clinical Trials 130

Drug Discovery World

SEPTEMBER 6, 2022

DDW Editor Reece Armstrong looks at the cell and gene therapy landscape, examining the challenges facing developers and the trends we can expect to see throughout the year. . There’s no doubt that cell and gene therapies present some of the most exciting opportunities for emerging drugs. billion, compared to $19.9 Cancer is king .

Therapies 130

Therapies Clinical Trials Vaccine Disease 130

Drug Discovery World

NOVEMBER 4, 2022

In a week that saw magic mushrooms making the headlines in the UK, we also reported on exciting potential new therapies for geographic atrophy and malaria prevention. Covid-19 vaccine less effective in the immunocompromised . Covid-19 vaccine less effective in the immunocompromised . The top stories: .

Vaccine 130

Vaccine Therapies Drugs Virus 130

Vial

DECEMBER 11, 2023

Hepatitis C virus (HCV) infection is a global health problem with complications that place a significant economic burden on national health systems. Pathophysiological evidence links HCV infections to the risk of liver diseases such as hepatocellular carcinoma (HCC) and liver cirrhosis. However, challenges in eliminating HCV persist.

Clinical Research 52

Clinical Research Therapies Research Vaccine 52

Drug Discovery World

JULY 22, 2022

Covid-19 vaccines remain effective six months after second dose . Two doses of Covid-19 vaccines were sufficient in providing protection against severe cases of the infectious disease, according to new research.? . New combination therapy shows promise against lung cancers? .

DNA 130

DNA Clinical Trials Vaccine Virus 130

Drug Discovery World

JUNE 7, 2023

How important will mRNA-based vaccines be in treating viruses and diseases such as cancer? What can we expect from the cell & gene therapy market? Panellists will discuss the following questions: Where will the opportunities be in 2024? Is it true that the next era will belong to antibody drug conjugates?

DNA 130

DNA Clinical Trials Drugs Vaccine 130

Drug Discovery World

JANUARY 9, 2023

It is hoped that a new partnership between the UK government and BioNTech will help accelerate clinical trials of personalised immunotherapies for cancer and infectious disease vaccines. . The agreement means cancer patients will get early access to trials exploring personalised mRNA therapies, like cancer vaccines. .

Research 130

Research Vaccine Government Clinical Trials 130

Drug Discovery World

JUNE 27, 2023

How important will mRNA-based vaccines be in treating viruses and diseases such as cancer? What can we expect from the cell & gene therapy market? Roundtable panelists include Commercial Research Scientist Dr Mark Treherne, CEO of Elevation Oncology, Joe Ferra, and CEO of BioXcel Therapeutics, Vimal Mehta.

DNA 130

DNA Clinical Trials Drugs Vaccine 130

Drug Discovery World

JUNE 22, 2023

How important will mRNA-based vaccines be in treating viruses and diseases such as cancer? What can we expect from the cell & gene therapy market? Roundtable panelists include Commercial Research Scientist Dr Mark Treherne, CEO of Elevation Oncology, Joe Ferra, and CEO of BioXcel Therapeutics, Vimal Mehta.

DNA 130

DNA Clinical Trials Drugs Vaccine 130

Drug Discovery World

JUNE 15, 2023

How important will mRNA-based vaccines be in treating viruses and diseases such as cancer? What can we expect from the cell & gene therapy market? Roundtable panelists include Commercial Research Scientist, Dr Mark Treherne, CEO of Elevation Oncology, Joe Ferra, and CEO of BioXcel Therapeutics, Vimal Mehta.

DNA 130

DNA Clinical Trials Drugs Vaccine 130

Drug Target Review

MAY 22, 2024

How does Circio’s circVec technology aim to enhance the potency and reduce the cost of current gold-standard gene therapy? As a first step, Circio is working on designing and validating circVec-AAV vectors for the treatment of genetic diseases, and testing these head-to-head against the mRNA-AAV equivalent in vivo.

Therapies 57

Therapies RNA Protein Expression DNA 57

Drug Discovery World

JUNE 8, 2023

How important will mRNA-based vaccines be in treating viruses and diseases such as cancer? What can we expect from the cell & gene therapy market? Roundtable panelists include Commercial Research Scientist Dr Mark Treherne, CEO of Elevation Oncology, Joe Ferra, and CEO of BioXcel Therapeutics, Vimal Mehta.

DNA 130

DNA Drugs Clinical Trials Vaccine 130

Drug Discovery World

JANUARY 9, 2024

They include therapeutics for conditions including breast cancer, haemophilia A, sickle cell disease, Crohn’s disease, ulcerative colitis, respiratory syncytial virus (RSV) and multiple myeloma, among others. The therapy has shown positive results in Phase III trials in both breast and lung cancer.

Drugs 173

Drugs Therapies Treatment Virus 173

Drug Discovery World

SEPTEMBER 14, 2023

Total revenue from oncology medicines increased 22%, CVRM 20%, R&I8 10%, and rare disease 12%. Vaccines were up 9.1% Moreover, in July 2023, AstraZeneca and Vaxess Technologies commenced a collaboration for the evaluation of a novel RNA-based pandemic influenza prototype vaccine in patch format. Specialty care grew 11.8%

Vaccine 147

Vaccine FDA Approval Drugs Licensing 147

Drug Discovery World

JULY 20, 2023

Elevidys, Sarepta Therapeutics Elevidys became the first gene therapy for Duchenne muscular dystrophy (DMD) to gain marketing authorisation in the US in June this year. The drug was also approved in children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

FDA Approval 100

FDA Approval FDA Virus Therapies 100

The Pharma Data

APRIL 26, 2022

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. NYSE: PFE) today reported positive Phase 2 pediatric data for their Lyme disease vaccine candidate, VLA15.

Vaccine 52

Vaccine Disease Protein Expression Trials 52

Drug Discovery World

JULY 14, 2022

Pharmaceutical company SIGA Technologies has announced that its oral therapy tecovirimat has been approved in the UK for the treatment of smallpox, monkeypox, cowpox. . The therapy has also been approved for the treatment of complications following vaccination against smallpox in adults and children with a body weight of at least 13kg. .

Treatment 130

Treatment Pharmaceutical Companies Vaccine Virus 130

Drug Discovery World

FEBRUARY 10, 2023

The top stories: Study shines a light on representation in clinical research A diversity study has shown that clinical trials should use real world diseases epidemiology data, rather than US Census Bureau race and ethnicity data, to ensure enrolment reflects the populations affected by different diseases.

Clinical Trials 130

Clinical Trials Trials Drugs Vaccine 130

Drug Discovery World

JANUARY 22, 2024

It states: ” An integrated appreciation of the physiological consequences of DUB modulation in relevant cancer models will eventually lead to the identification of patient populations that will most likely benefit from DUB-targeted therapies” 1.

Immune Response 147

Immune Response Vaccine Engineering Virus 147

Drug Discovery World

AUGUST 18, 2023

My chosen news stories this week all discuss pre-clinical research studies that could have a huge impact on our therapeutic approach to several hard-to-treat diseases, helping to overcome drug-resistance and make treatments more targeted in the future.

Small Molecule 130

Small Molecule Virus Drugs Clinical Research 130

Drug Discovery World

OCTOBER 24, 2022

New research suggests messenger RNA can be effectively used as a ‘universal’ therapy against different coronaviruses. . Rather than messenger RNA as a vaccine, this shows that mRNA can be used as a universal therapy against different coronaviruses,” said Gaurav Sahay, OSU and the Texas Biomedical Research Institute.

Treatment 100

Treatment RNA Protein Production Packaging 100

Drug Discovery World

JULY 24, 2023

The following novel medicines and biosimilars each received a positive opinion: Abrysvo (bivalent, recombinant) , a vaccine to protect small infants and older people against lower respiratory tract disease caused by respiratory syncytial virus (RSV).

Biosimilars 130

Biosimilars Virus Treatment Marketing 130

The Pharma Data

JULY 21, 2021

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, and Pfizer Inc. at Month 7). Juan Carlos Jaramillo M.D., About VLA15.

Vaccine 52

Vaccine Disease Trials Protein Expression 52

Drug Discovery World

AUGUST 30, 2022

It limits viral spread in the body by inhibiting the work of the protein involved in the release of the enveloped virus. Recently, the Centers for Disease Control and Prevention (CDC) allowed physicians to prescribe tecovirimat on a compassionate use basis to treat adults and children with orthopoxvirus infections, including monkeypox.

Therapies 130

Therapies FDA Approval Vaccine Treatment 130

Drug Discovery World

MAY 25, 2023

The aim of the researchers is to understand the mechanisms that regulate cancer cell proliferation, survival and dissemination; to identify critical components of these pathways as targets for novel cancer therapies; and to help translate this knowledge to patient benefit.

Research 130

Research Virus Drugs Disease 130

The Pharma Data

SEPTEMBER 30, 2021

As one among the leading global vaccines companies, we still bring options which help protect people’s health round the world,” said Michael Greenberg, MD, MPH, Medical Head, Sanofi Pasteur North America. “We 4,5 Anyone can get meningococcal disease, but teens and young adults are among those that are at the very best risk for the infection.6,7

Vaccine 52

Vaccine Research Virus Hospitals 52

Drug Discovery World

MAY 22, 2023

Cell therapy, RNA technology, antibody drug conjugates and AI/machine learning are among the key areas of investment for pharma, according to a new report. Clarivate’s ‘Biopharma Dealmaking in 2023’ report examines how pharma companies are replenishing their pipelines as many face a steep patent cliff.

Pharma Companies 130

Pharma Companies RNA Therapies Virus 130

Codon

JANUARY 21, 2024

Today, refined versions of these human challenge studies have become standard practice in testing vaccines for vector-borne diseases (e.g., yellow fever, malaria, and dengue), evaluating new drugs or treatments, and studying pathogenesis, the process by which a disease develops. Why are challenge trials becoming more popular?

Vaccine 132

Vaccine Trials Disease Virus 132

The Pharma Data

AUGUST 16, 2021

The study assessed cynomolgus macaques vaccinated with 12µg of either the first or second-generation vaccine candidate. During challenge with the original SARS-CoV-2 virus, animals vaccinated with CV2CoV were found to be better protected based on highly effective clearance of the virus in the lungs and nasal passages.

Immune Response 52

Immune Response Vaccine Virus RNA 52

The Pharma Data

JANUARY 31, 2021

Adjuvanted S-Trimer COVID-19 vaccine candidates demonstrated favorable safety and tolerability profiles and strong neutralizing immune responses in a phase 1 trial. Clover plans to initiate a global phase 2/3 trial in the first half of 2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021.

Clinical Trials 52

Clinical Trials Vaccine Trials Virus 52

Advarra

JUNE 13, 2024

Because these therapies often use live viral vectors, there is the risk of accidental transmission that is not encountered with non-biological drugs and therapeutics. Replication-competent Agents On the other side of the risk spectrum, live replication-competent viruses are being developed as therapies for solid tumors.

Clinical Trials 52

Clinical Trials Engineering Trials Virus 52

The Pharma Data

MARCH 14, 2023

QDENGA is the only dengue vaccine approved in Brazil for use in individuals regardless of previous exposure to dengue and without the need for pre-vaccination testing. QDENGA is the only dengue vaccine approved in Brazil for use in individuals regardless of previous exposure to dengue and without the need for pre-vaccination testing.

Vaccine 40

Vaccine Virus Hospitals Trials 40